Acute thrombocytopenia after De-Nol.

Beckingham, I. J.; Baird, G; Kesteven, Patrick

doi:10.1136/gut.30.7.1016

Cited by 5 publications

(2 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Consequently, it should not be used in those with renal failure, and not in the long term until long term safety has been established. One case of severe thrombocytopenia in an elderly male has been reported, [163] and I case of encephalopathy has been described in a 68-yearold male with chronic renal failure who took twice the recommended dose of TDB. [58] The local symptoms caused by TDB, including staining of the tongue and teeth, interfere with patient compliance.…”

Section: Tripotassium Dicitrato Bismuthate (Bismuth Subcitrate)mentioning

confidence: 97%

A Comparative Overview of the Adverse Effects of Antiulcer Drugs

Piper

1995

Drug Safety

View full text Add to dashboard Cite

During the past 2 decades, great advances have been made in the treatment of ulcer disease. This has involved the development of new drugs that are not only well tolerated, but are relatively inexpensive. The lack of significant adverse effects has revealed a degree of tolerability that, to write a review of the adverse effects, poses a difficult task. Most of the adverse effects are related to an excessive reaction to the relevant pharmacological characteristic that mediates the therapeutic response. The drug dosage can be reduced, freeing the patient of the adverse reaction, but leaving behind a background activity adequate to produce a therapeutically beneficial effect. The adverse effects of H2-antagonists fall into 2 groups. Firstly, there are poorly defined symptoms that have a prevalence similar to that in the community; these include headache, giddiness, dizziness, fatigue, constipation and diarrhoea. Secondly, they may delay the metabolism of drugs metabolised by the the cytochrome P450 system, and rarely be androgenic. Many antacids and the site-protective agent sucralfate contain aluminium, which can be absorbed, producing elevation of serum aluminium levels. In view of the possible association of aluminium with Alzheimer's disease, anxiety has arisen as to whether aluminium from these sources may, in those on prolonged treatment, cause Alzheimer's disease. However, the evidence so far indicates that aluminium is not a risk factor for Alzheimer's disease. The association of gastric cancer with achlorhydria has led to the fear that long term use of potent acid inhibitors may cause cancer. This fear has been accentuated by the observation that some rats, given omeprazole over their lifetime, developed carcinoid tumours of the stomach. However, enthusiastic research, both clinical and epidemiological, indicates that drug-induced achlorhydria is unlikely to be a problem in humans. Site protective agents have a role in certain conditions such as pregnancy where the systemic effect of a drug may produce adverse effects.

show abstract

Section: Tripotassium Dicitrato Bismuthate (Bismuth Subcitrate)mentioning

confidence: 97%

A Comparative Overview of the Adverse Effects of Antiulcer Drugs

Piper

1995

Drug Safety

View full text Add to dashboard Cite

show abstract

“…Οι Beckingham και συν. (313), αναφέρουν σοβαρή οξεία θρομβοπενία μετά τη λήψη CBS για χρό νο μικρότερο των δύο εβδομάδων.…”

Section: η ανεπιθυμητες ενεργειεςunclassified

Διάγνωση και παρακολούθηση ασθενών με γαστρίτιδα και Helicobacter (Campylobacter) pylori

Σαλαμέτης¹

View full text Add to dashboard Cite

show abstract

The Role of Helicobacter pylori in Peptic Ulcer Disease

Partipilo,

Woster

1993

Pharmacotherapy

View full text Add to dashboard Cite

The pathophysiology of peptic ulcer disease (PUD) is often described as an imbalance between aggressive factors such as acid and pepsin and alterations in the mucosal protective mechanisms. Helicobacter pylori is a gram‐negative organism that has been identified as a potential causative agent in the pathogenesis of PUD. The exact mechanism by which it contributes to mucosal damage is unknown. It is thought that the organism may disrupt the protective mucous layer, allowing the underlying epithelium to be injured by gastric acid. Significant evidence indicates that H. pylori is a major etiologic factor in type B gastritis. Data confirming its etiologic role in duodenal ulcer (DU) disease is not conclusive; however, eradication of the organism is associated with a reduction in the recurrence of DU. Optimum therapy to eradicate H. pylori has not been established, although several multidrug regimens have been evaluated. Treatment of H. pylori infection should be reserved for individuals in whom conventional therapy for DU is unsuccessful and those whose ulcers relapse during maintenance therapy.

show abstract

Acute thrombocytopenia after De-Nol.

Cited by 5 publications

References 3 publications

A Comparative Overview of the Adverse Effects of Antiulcer Drugs

A Comparative Overview of the Adverse Effects of Antiulcer Drugs

Διάγνωση και παρακολούθηση ασθενών με γαστρίτιδα και Helicobacter (Campylobacter) pylori

The Role of Helicobacter pylori in Peptic Ulcer Disease

Contact Info

Product

Resources

About